术前应用雷珠单抗辅助玻璃体手术治疗糖尿病性视网膜病变的效果分析

Effect of preoperative application of ranibizumab-assisted vitreous surgery for diabetic retinopathy

目的研究术前应用雷珠单抗辅助玻璃体手术治疗糖尿病性视网膜病变的效果。方法选择2017年9月至2018年9月本院收治的40例行玻璃体手术糖尿病性视网膜病变患者作为研究对象,按照数字随机分组方式将其划分成实验组与对照组,各20例。对照组接受玻璃体手术治疗,实验组接受玻璃体手术前注射雷珠单抗治疗,对比两组患者各项指标、视力改善率、术后并发症发生率。结果经比较,实验组各项指标、视力改善率、术后并发症发生率均优于对照组,两组比较差异有统计学意义(P<0.05)。结论行玻璃体手术前应用雷珠单抗,能够有效改善糖尿病性视网膜病变症状,提高患者视力改善程度,降低术后并发症发生率,值得临床推广与应用。

Objective To study the effect of preoperative ranibizumab-assisted vitreous surgery for diabetic retinopathy. Methods Forty patients with vitreoretinal retinopathy who underwent vitreous surgery from September 2017 to September 2018 were enrolled in the study. They were divided into two groups according to numerical randomization, named experimental group and control group, with 20 cases in each group. The control group received vitreous surgery. The experimental group received ranibizumab before vitreous surgery. The indexes, visual acuity improvement rate and postoperative complication rate were compared between the two groups. Results After comparison, the indexes, visual acuity improvement rate and postoperative complication rate of the experimental group were superior to the control group. There was significant difference between the two groups(P<0.05). Conclusion The application of ranibizumab before vitreous surgery can effectively improve the symptoms of diabetic retinopathy, improve the degree of visual acuity improvement, and reduce the incidence of postoperative complications. It is worthy of clinical promotion and application.